A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

Coignard, J Lush, M Beesley, J O'Mara, TA Dennis, J Tyrer, JP Barnes, DR McGuffog, L Leslie, G Bolla, MK Adank, MA Agata, S Ahearn, T Aittomäki, K Andrulis, IL Anton-Culver, H Arndt, V Arnold, N Aronson, KJ Arun, BK Augustinsson, A Azzollini, J Barrowdale, D Baynes, C Becher, H Bermisheva, M Bernstein, L Białkowska, K Blomqvist, C Bojesen, SE Bonanni, B Borg, A Brauch, H Brenner, H Burwinkel, B Buys, SS Caldés, T Caligo, MA Campa, D Carter, BD Castelao, JE Chang-Claude, J Chanock, SJ Chung, WK Claes, KBM Clarke, CL GEMO Study Collaborators, EMBRACE Collaborators, Collée, JM Conroy, DM Czene, K Daly, MB Devilee, P Diez, O Ding, YC Domchek, SM Dörk, T Dos-Santos-Silva, I Dunning, AM Dwek, M Eccles, DM Eliassen, AH Engel, C Eriksson, M Evans, DG Fasching, PA Flyger, H Fostira, F Friedman, E Fritschi, L Frost, D Gago-Dominguez, M Gapstur, SM Garber, J Garcia-Barberan, V García-Closas, M García-Sáenz, JA Gaudet, MM Gayther, SA Gehrig, A Georgoulias, V Giles, GG Godwin, AK Goldberg, MS Goldgar, DE González-Neira, A Greene, MH Guénel, P Haeberle, L Hahnen, E Haiman, CA Håkansson, N Hall, P Hamann, U Harrington, PA Hart, SN He, W Hogervorst, FBL Hollestelle, A Hopper, JL Horcasitas, DJ Hulick, PJ Hunter, DJ Imyanitov, EN KConFab Investigators, HEBON Investigators, ABCTB Investigators, Jager, A Jakubowska, A James, PA Jensen, UB John, EM Jones, ME Kaaks, R Kapoor, PM Karlan, BY Keeman, R Khusnutdinova, E Kiiski, JI Ko, Y-D Kosma, V-M Kraft, P Kurian, AW Laitman, Y Lambrechts, D Le Marchand, L Lester, J Lesueur, F Lindstrom, T Lopez-Fernández, A Loud, JT Luccarini, C Mannermaa, A Manoukian, S Margolin, S Martens, JWM Mebirouk, N Meindl, A Miller, A Milne, RL Montagna, M Nathanson, KL Neuhausen, SL Nevanlinna, H Nielsen, FC O'Brien, KM Olopade, OI Olson, JE Olsson, H Osorio, A Ottini, L Park-Simon, T-W Parsons, MT Pedersen, IS Peshkin, B Peterlongo, P Peto, J Pharoah, PDP Phillips, K-A Polley, EC Poppe, B Presneau, N Pujana, MA Punie, K Radice, P Rantala, J Rashid, MU Rennert, G Rennert, HS Robson, M Romero, A Rossing, M Saloustros, E Sandler, DP Santella, R Scheuner, MT Schmidt, MK Schmidt, G Scott, C Sharma, P Soucy, P Southey, MC Spinelli, JJ Steinsnyder, Z Stone, J Stoppa-Lyonnet, D Swerdlow, A Tamimi, RM Tapper, WJ Taylor, JA Terry, MB Teulé, A Thull, DL Tischkowitz, M Toland, AE Torres, D Trainer, AH Truong, T Tung, N Vachon, CM Vega, A Vijai, J Wang, Q Wappenschmidt, B Weinberg, CR Weitzel, JN Wendt, C Wolk, A Yadav, S Yang, XR Yannoukakos, D Zheng, W Ziogas, A Zorn, KK Park, SK Thomassen, M Offit, K Schmutzler, RK Couch, FJ Simard, J Chenevix-Trench, G Easton, DF Andrieu, N Antoniou, AC
Publisher:
Springer Science and Business Media LLC
Publication Type:
Journal Article
Citation:
Nature communications, 2021, 12, (1), pp. 1078
Issue Date:
2021-02-17
Full metadata record
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Please use this identifier to cite or link to this item: